BR112023004262A2 - Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio - Google Patents

Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio

Info

Publication number
BR112023004262A2
BR112023004262A2 BR112023004262A BR112023004262A BR112023004262A2 BR 112023004262 A2 BR112023004262 A2 BR 112023004262A2 BR 112023004262 A BR112023004262 A BR 112023004262A BR 112023004262 A BR112023004262 A BR 112023004262A BR 112023004262 A2 BR112023004262 A2 BR 112023004262A2
Authority
BR
Brazil
Prior art keywords
binding site
methods
mass spectrometry
hydrogen exchange
exchange mass
Prior art date
Application number
BR112023004262A
Other languages
English (en)
Inventor
Zhang Sisi
Xiao Hui
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112023004262A2 publication Critical patent/BR112023004262A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Hydrogen, Water And Hydrids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MÉTODOS PARA IDENTIFICAÇÃO DO SÍTIO DE LIGAÇÃO USANDO ESPECTROMETRIA DE MASSA DE TROCA DE HIDROGÊNIO. A presente invenção refere-se a métodos para identificar um sítio de ligação entre um produto farmacêutico de proteína e uma proteína de célula hospedeira (HCP) usando espectrometria de massa de troca de hidrogênio. O presente pedido também fornece métodos para modificar produtos farmacêuticos de proteína para eliminar a clivagem ou modificação por HCPs. Além disso, o presente pedido fornece métodos para bloquear o sítio de ligação identificado em produtos farmacêuticos de proteína para eliminar a clivagem ou modificação por HCPs.
BR112023004262A 2020-09-11 2021-09-11 Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio BR112023004262A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063077220P 2020-09-11 2020-09-11
PCT/US2021/049975 WO2022056336A1 (en) 2020-09-11 2021-09-11 Methods for binding site identification using hydrogen exchange mass spectrometry

Publications (1)

Publication Number Publication Date
BR112023004262A2 true BR112023004262A2 (pt) 2023-04-04

Family

ID=78333247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004262A BR112023004262A2 (pt) 2020-09-11 2021-09-11 Métodos para identificação do sítio de ligação usando espectrometria de massa de troca de hidrogênio

Country Status (11)

Country Link
US (1) US20220082571A1 (pt)
EP (1) EP4211255A1 (pt)
JP (1) JP2023542858A (pt)
KR (1) KR20230066025A (pt)
CN (1) CN116490777A (pt)
AU (1) AU2021342274A1 (pt)
BR (1) BR112023004262A2 (pt)
CA (1) CA3194955A1 (pt)
IL (1) IL301234A (pt)
MX (1) MX2023002924A (pt)
WO (1) WO2022056336A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604345B2 (ja) * 2000-12-21 2011-01-05 住友化学株式会社 タンパク質のｎ末端のアミノ酸配列決定方法
JP2005504263A (ja) * 2001-02-01 2005-02-10 シファーゲン バイオシステムズ， インコーポレイテッド タンデム質量分析によるタンパク質同定、特徴付けおよび配列決定のための改良された方法
AU2003221860A1 (en) * 2002-04-10 2003-10-27 The Regents Of The University Of California Improved methods for high-resolution identification of solvent-accessible amide hydrogens in polypeptides and for characterization of polypeptide structure
WO2006020498A2 (en) * 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
EP2207799A2 (en) * 2007-10-19 2010-07-21 Pronota NV Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
CN102308216B (zh) * 2009-02-09 2014-07-09 罗切格利卡特公司 免疫球蛋白糖基化模式分析
CA2833212C (en) * 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
US10281473B2 (en) * 2014-02-04 2019-05-07 University Of Virginia Patent Foundation Compositions and methods for analysis of protein sequences and post-translational modifications
WO2017097918A1 (en) * 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Method for determining the in vivo interaction mode
EP3387439B1 (en) * 2015-12-09 2020-02-26 H. Hoffnabb-La Roche Ag Direct affinity measurement of human igg1 binding multimeric antigens
EP3485280A1 (en) * 2016-08-12 2019-05-22 Lonza Ltd Proteomic analysis of host cell proteins

Also Published As

Publication number Publication date
JP2023542858A (ja) 2023-10-12
WO2022056336A1 (en) 2022-03-17
KR20230066025A (ko) 2023-05-12
AU2021342274A1 (en) 2023-04-27
US20220082571A1 (en) 2022-03-17
IL301234A (en) 2023-05-01
CA3194955A1 (en) 2022-03-17
MX2023002924A (es) 2023-04-10
CN116490777A (zh) 2023-07-25
EP4211255A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
BR112022017048A2 (pt) Anticorpos contra sars-cov-2 e métodos para usar os mesmos
CY1119412T1 (el) Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
BR112019005129A2 (pt) anticorpos anti-pd-1
BR112018002553A8 (pt) Sais de um inibidor de lsd1
BR112019007977A2 (pt) composto, composição farmacêutica, método de tratamento ou prevenção de câncer, e, uso de um composto
NO20075635L (no) Antigenbindende molekyler som har modifiserte Fc-regioner og endret binding til Fc-reseptorer
JP2019506866A5 (pt)
WO2018226685A3 (en) METHODS FOR THE SENSITIZATION OF CANCER CELLS TO MEDIATED DESTRUCTION BY T-LYMPHOCYTES BY MOLECULAR PATHWAY MODULATION
BR112016018205A2 (pt) métodos de tratamento de mal de alzheimer
ATE433124T1 (de) System und verfahren zum analysieren von radarinformationen
BRPI0517559A (pt) composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos
BR112018015590A2 (pt) modulação de receptor acoplado à proteína g (gpcr) por imipridonas
CO6640290A2 (es) Sistema y método para personalizar solicitudes en tiempo real en una interaz de usuario
BR112013025629A2 (pt) padrão quantitativo para espectrometria de massa de proteínas
BRPI0607793A2 (pt) processo para a preparação de moduladores opióides
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
WO2007041820A3 (en) A method for identifying protein patterns in mass spectrometry
BRPI0923582B1 (pt) método, dispositivo, programa e meio de registro de análise da causa de recuperação elástica.
BR112023021978A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
BR112021020360A2 (pt) Método, dispositivo de usuário, módulo de veículo e sistema para autenticar uma conexão entre um dispositivo de usuário e um veículo
BR112023001517A2 (pt) Relatório de informações relacionadas à integridade para posicionamento
CY1113816T1 (el) Μορια ταυτοποιησης τα οποια ρυθμιζουν τις αλληλεπιδρασεις πρωτεϊνης-πρωτεϊνης με τη χρηση ανταποκριτων που ενεργοποιουνται με μια πρωτεαση
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
BRPI0501535B8 (pt) método de identificação do guignardia citricarpa